To promote the development of the pharmaceutical and healthcare industry, the Administration Committee of Beijing Daxing International Airport Economic Zone issued 5 supporting policies on July 7 covering Daxing Cluster in the high-end industrial area of China (Beijing) Pilot Free Trade Zone and Beijing Daxing International Airport Area of China (Hebei) Pilot Free Trade Zone.

Those policies provide support for biopharmaceuticals, cell therapy, high-end medical consumables and implantable devices, genetic testing and precision medicine, commercialization of medical-industrial results, and more. Those policies focus on the following five aspects:

Industrialization of achievements - If an enterprise which has newly obtained certificates and production approval for Class I biologicals or Class III medical equipment produces or settles payment in the Airport Economic Zone, a one-time reward of CNY 3 million per item will be granted, with an annual maximum of CNY 10 million for each enterprise.

Mass production - Support the cultivation of basic researches of the life health industry. For each large piece of drug and medical equipment produced or settled in the Airport Economic Zone, if the annual output value exceeds CNY 50 million, CNY 100 million and CNY 300 million for the first time, a one-time respective reward of CNY 500,000, CNY 1 million and CNY 1.5 million will be granted.

International development - Support the world's top 500 and world-leading life and health enterprises to set up regional headquarters and R&D centers in the Airport Economic Zone. Upon review and approval, 10 percent of the total fixed asset investment (excluding land costs) will be granted to such enterprises, with an annual maximum of CNY 60 million for each.

Construction of public platforms – Advocate for the construction of specialized R&D and production service platforms. Efforts are taken to accelerate the cultivation and introduction of R&D and production service platforms that specialize in biomedicine, such as industry-leading contract research organizations (CRO) and contract development and manufacturing organizations (CDMO). Platforms will be supported on a merit basis, with a financial reward of not more than CNY 30 million, equivalent to 30 percent of the total project investment in production lines construction, equipment purchase, etc.. Support will be given to the construction of testing and inspection service platforms.

Construction of medical service institutions - Encourage the construction of medical service institutions such as clinical research hospitals, clinical trial institutions and clinical medicine research centers to promote the development of emerging services such as precision medicine, genetic testing, translational medicine and health management and offer such institutions support in terms of their establishment and operation.

(Note: Content source is from Chinanews.com)